A participant in a psychedelic therapy clinical trial rarely interacts with just one professional. Before treatment begins, they typically pass through the hands of a study coordinator, a psychiatrist conducting assessment, and often a rater tracking symptoms, each contributing a distinct piece of the process. The therapist enters partway through, not at the start and not alone. This distribution of roles is not incidental. It reflects where the field currently stands: psychedelic therapy is still working out who does what.

The roles taking shape today, particularly in clinical research and ketamine-assisted psychotherapy, will likely inform how the field organizes care if FDA approval moves forward, or if state initiatives continue to expand access to natural medicine. It is worth saying plainly that there is not yet a universal blueprint. Each state initiative legalizing natural medicine is building its own regulatory framework and its own role definitions, and clinical trials vary just as much, shaped by trial protocol, the study drug in question, and the sponsor running it. No one working in this space can say with certainty what it will look like in five or ten years. What can be done is to look closely at what is happening now for some indication of what might emerge.

The clinical trial team

The clinical trial model is deliberately distributed. A participant typically moves through several distinct roles before treatment concludes, each with its own scope of practice and training requirements.

The study coordinator is usually the first point of contact. This person conducts preliminary screening and intake, providing information about the trial's broad exclusion and inclusion criteria. It is worth noting that study coordinators are not necessarily licensed and do not require a specific mental health background, though many bring that expertise regardless.

From there, participants generally move into a more comprehensive assessment, typically conducted by a psychiatrist or another qualified clinician. This phase involves detailed history taking, review of diagnostic documentation, and screening for safety considerations specific to the study.

Many trials also employ remote raters, who assess the severity of the symptoms the trial is designed to address. Their work provides an objective measure of treatment effects over the course of the study.

The study therapist, generally a licensed psychotherapy practitioner, is present throughout preparation, the medicine session itself, and the integration period that follows. Depending on the trial, this person may also contribute to symptom rating and other assessments, though this varies considerably across studies.

Taken together, this is a coordinated effort across several professionals, not a single therapist working alone with a client. Each person brings distinct expertise to a different part of the process, and the quality of communication between these roles matters as much as the expertise of any one of them.

Ketamine-assisted psychotherapy: three models in practice

Ketamine is already available for clinical use, so how it is delivered today offers a useful, if imperfect, preview of how other psychedelics might be delivered once approved. Three models are common, each shaping the client experience in different ways.

The clinic model

In a traditional clinic, an administrative coordinator usually serves as the first point of contact, handling scheduling, pricing, and logistics before connecting the client with a prescriber.

The prescriber's role is central. This is the professional who determines suitability for treatment, sets dosage, and develops the overall treatment plan, including how often sessions occur. The prescriber then coordinates with a therapist, either someone already in the client's care network or a staff member at the clinic.

That therapist provides preparation, guides the medicine session, and supports integration afterward. Some clinics offer extensive preparation and integration work with licensed psychotherapists, while others rely on integration coaches with varying credentials. A medical director typically oversees the clinic as a whole, responsible for the safety and quality of care delivered. Clinic structures vary considerably, and there is no single standard model.

The office-based remote prescriber model

In this model, a client may meet a prescriber by telehealth for a basic suitability assessment. If appropriate, the prescriber sends a prescription to a pharmacy for the client to pick up, and the client then has their medicine session in a therapist's office rather than a specialized clinic.

Here, the client is responsible for monitoring their own vital signs, checking heart rate and blood pressure against thresholds set by the prescriber. Ketamine is typically self-administered orally, while the therapist remains present to facilitate the experience. This model offers more flexibility and accessibility than the traditional clinic setting, though it also shifts more of the safety monitoring onto the client, a tradeoff worth noting rather than glossing over.

The fully remote model

The most distributed approach involves a fully remote setup, in which even the therapist connects by telemedicine while the client is at home. This represents the furthest extension of accessibility, and it raises real questions about support and safety that practitioners are still actively working through.

What this suggests about the field's direction

Ketamine's relatively short duration of action may make it better suited to these varied delivery models than other psychedelics currently in development. Compounds with longer-acting profiles will likely require different adaptations, and it would be premature to assume the ketamine models translate directly.

The roles described here (coordinators, prescribers, therapists, medical directors) offer a reasonable preview of what broader psychedelic therapy delivery might resemble. It is worth stating plainly that this remains an open question. The field is genuinely in flux, and the regulatory environment will play a significant role in shaping which roles take hold and how they are defined.

What does seem clear is that psychedelic therapy is moving toward team-based delivery rather than a model built around a single therapist and client. That direction makes sense given what the work actually requires: clinical assessment, prescribing authority, psychological support, and careful attention to Psychedelic Harm Reduction and Integration.

Where this leaves clinicians

For clinicians entering this field, or already working within it, understanding these roles and delivery models is a reasonable place to start. The landscape is still shifting, and there is more for the field to learn before any of this settles into a fixed shape.